Transcriptogen Overview

  • Founded
  • 2013
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Transcriptogen General Information


Developer of a drug discovery platform intended to identify novel transcription factor inhibitors for its pipeline for future clinical development. The company's drug discovery platform offers TSG-1301, a potent DNA-interactive NF-kB inhibitor, that exploits the use of small molecules to inhibit the interaction of transcription factors, enabling patients with up-regulated or dysregulated TF-based signaling pathways to be selected for clinical trials and treatment.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Paragon House
  • Lyncombe Vale Road
  • Bath BA2 4LS
  • England, United Kingdom
+44 01225 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Transcriptogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Oct-2017 00000 Completed Out of Business
3. Early Stage VC 01-Apr-2017 Cancelled Clinical Trials - Phase 1
2. Seed Round 21-Apr-2016 $199K $199K 00000 Completed Startup
1. Grant $3.13M Completed Startup
To view Transcriptogen’s complete valuation and funding history, request access »

Transcriptogen Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 00.000000 000.00 000.00 00 000.00 00.000
To view Transcriptogen’s complete cap table history, request access »